The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Chiesi’s idebenone within ...

US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing ...

The Parkinson’s disease (PD) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK and Japan ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

Shares of US clinical-stage company Eledon Pharmaceuticals shot up 9.9% to close at $3.44 yesterday, after it announced ...

US pharma major Eli Lilly’s shares plunged more than 14% to $630.61 after it announced what was seen by the market ...

China-based Everest Medicines (HKEX: 1952) has secured full regulatory approval for Nefecon (budesonide) in Taiwan, marking the last of its Asian territories to grant the go-ahead for the ...

Swiss generics and biosimilar major Sandoz today presented its financial results for the first half of 2025. and reiterated ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Ireland-headquartered Jazz Pharmaceuticals’ ...

Merck & Co (NYSE: MRK) was the biggest spender in pharma M&A during July. The US pharma giant boldly splashed out around $10 ...

USA-based biotech DoveTree Medicines has signed a far-reaching partnership with Chinese drug discovery company XtalPi (HKEX: 2228), in a deal worth up to $5.99 billion.

The initial small tariff on pharmaceutical imports will be increased to 150% within 18 months and eventually to 250%, according to President Trump’s comments in a CNBC interview.